{"id":"W2116048670","doi":"10.1136/ard.2008.102103","title":"Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases","year":2009,"lang":"en","type":"review","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":203,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Regeneron Pharmaceuticals; Procter and Gamble; GlaxoSmithKline; AstraZeneca; Pfizer; Amgen; Bristol-Myers Squibb; Abbott Laboratories","keywords":"Adalimumab; Medicine; Psoriatic arthritis; Ankylosing spondylitis; Population; Internal medicine; Psoriasis; Rheumatoid arthritis; Malignancy; Clinical trial; Infliximab; Mortality rate; Arthritis; Standardized mortality ratio; Disease; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001101309,0.0005996526,0.007185746,0.00006409785,0.0001114004,0.00002226527,0.0003401315,0.0002396065,0.0001492042],"category_scores_gemma":[0.00975243,0.0003422373,0.002956021,0.0002727426,0.0005841239,0.00007662773,0.0002691805,0.0001685926,0.00001241564],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003840175,"about_ca_system_score_gemma":0.0006426047,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002582746,"about_ca_topic_score_gemma":0.00002050363,"domain_scores_codex":[0.992659,0.001685877,0.004243073,0.0004749846,0.0006131064,0.0003239501],"domain_scores_gemma":[0.9914381,0.003765566,0.003124543,0.00109849,0.0002143684,0.0003589555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0006862662,0.001414119,0.03377706,0.0118211,0.008660261,0.00003305532,0.00002038242,3.236809e-7,4.017048e-8,0.00009144929,0.001446647,0.9420493],"study_design_scores_gemma":[0.005921154,0.0005588637,0.8081042,0.1005482,0.02832513,0.0000124711,0.00009860851,0.000007465993,0.000001529354,0.00172548,0.05416644,0.0005305114],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02331311,0.9605169,6.612216e-7,0.0001471526,0.00032066,0.001803558,0.01377733,0.00003607808,0.00008450177],"genre_scores_gemma":[0.01302379,0.9856413,0.00001373741,0.0000905421,0.0001052771,0.00005393307,0.001013924,0.0000307571,0.00002673737],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9415188,"threshold_uncertainty_score":0.999903,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1709962303489945,"score_gpt":0.473548971548869,"score_spread":0.3025527411998745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}